About: Immune-mediated approaches against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune-mediated approaches against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immune-mediated approaches against COVID-19
Creator	Acúrcio, Rita Carreira, Barbara Florindo, Helena Kleiner, Ron Liubomirski, Yulia Satchi-Fainaro, Ronit Tiram, Galia Vaskovich-Koubi, Daniella Yeini, Eilam
Source	Medline; PMC
abstract	The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The long incubation period of this new virus, which is mostly asymptomatic yet contagious, is a key reason for its rapid spread across the world. Currently, there is no worldwide-approved treatment for COVID-19. Therefore, the clinical and scientific communities have joint efforts to reduce the severe impact of the outbreak. Research on previous emerging infectious diseases have created valuable knowledge that is being exploited for drug repurposing and accelerated vaccine development. Nevertheless, it is important to generate knowledge on SARS-CoV-2 mechanisms of infection and its impact on host immunity, to guide the design of COVID-19 specific therapeutics and vaccines suitable for mass immunization. Nanoscale delivery systems are expected to play a paramount role in the success of these prophylactic and therapeutic approaches. This Review provides an overview of SARS-CoV-2 pathogenesis and examines immune-mediated approaches currently explored for COVID-19 treatments, with an emphasis on nanotechnological tools.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1038/s41565-020-0732-3
bibo:pmid	32661375
has license	no-cc
sha1sum (hex)	246eb0ed05487b824c56db347785920048f6b3d1
schema:url	https://doi.org/10.1038/s41565-020-0732-3
resource representing a document's title	Immune-mediated approaches against COVID-19
has PubMed Central identifier	PMC7355525
has PubMed identifier	32661375
schema:publication	Nat Nanotechnol
resource representing a document's body	covid:246eb0ed05487b824c56db347785920048f6b3d1#body_text
is schema:about of	named entity 'disease' named entity 'accelerated' named entity 'therapeutic' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'tools' named entity 'incubation period' named entity 'Therefore' named entity 'systems' named entity 'COVID-19' named entity 'immunity' named entity 'outbreak' named entity 'vaccine' named entity 'long' named entity 'scientific communities' named entity 'COVID-19' named entity 'nanotechnological' named entity 'COVID' named entity 'prophylactic' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'Immune-mediated' named entity 'virus' named entity 'COVID-19 pandemic' named entity 'COVID-19' named entity 'COVID' named entity 'genetically-modified' named entity 'clinical trials' named entity 'virus' named entity 'Center for Disease Control and Prevention' named entity 'immunosuppression' named entity 'tuberculosis' named entity 'tetanus' named entity 'human diseases' named entity 'IFN' named entity 'antivirals' named entity 'serine protease inhibitor' named entity 'adjuvants' named entity 'infection' named entity 'vaccine design' named entity 'chloroquine phosphate' named entity 'activator of transcription' named entity 'SARS-CoV' named entity 'Brazil' named entity 'SARS-CoV-2' named entity 'ribozyme' named entity 'infection' named entity 'corticosteroid' named entity 'host immunity' named entity 'mRNA' named entity 'infection' named entity 'viral entry' named entity 'CD147' named entity 'Leydig cells' named entity 'infectious diseases' named entity 'remdesivir' named entity 'IFN-γ' named entity 'high-risk' named entity 'COVID-19 vaccine' named entity 'LNP' named entity 'PDL-1' named entity 'viral replication' named entity 'pathogenic agent' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'Review ARticle' named entity 'prognosis' named entity 'antimicrobial peptides' named entity 'inflammatory condition' named entity 'SARS-CoV' named entity 'immune response' named entity 'PBMC' named entity 'SARS-CoV-2' named entity 'non-structural proteins'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software